Yohimbe - A Natural Supplement
Supplements No Comments »Yohimbe is an herbal or natural supplement extracted from the bark of the African tree pausinystalia yohimbe, which contains yohimbine, the active ingredient. In most dietary supplements, yohimbe is standardized to 3% yohimbine. Yohimbine is an alpha2-antagonist Human fat cells possess both alpha- and beta-adrenergic receptors. Catecholamines are able to stimulate lipolysis through beta-receptors, whereas they inhibit lipolysis through alpha2-receptors. The balance between these receptors controls the rate of lipolysis. Therefore, an increase in thermogenesis for fat-loss purposes could be achieved by either stimulating betareceptors or by blocking alpha2-receptors. Because yohimbine has alphaTantagonistic properties, this supplement could be used during fat-loss procedures to further increase the rate of lipolysis. This discussion will focus on the lipolytic effect of yohimbine. However, it should be noted that yohimbine is a prescription drug. No specific studies have been done on yohimbe.
Animal Studies
Oral or intravenous administration of yohimbine in dogs has resulted in a significant elevation in plasma free fatty acids and an increase in sympathetic nervous system activity. Norepinephrine was significantly elevated following yohimbine administration. Furthermore, chronic oral administration resulted in a reduction in body weight and in food intake, suggesting that alpha2antagonists may influence satiety. The lipolytic effect of yohimbine may result either from a direct action of yohimbine or from an activation of the sympathetic nervous system.
Human Studies
The interplay of beta-receptors and alphaTreceptors regulates the lipolytic response of adipose tissue to the catecholamines. A supplement which would inhibit the alpha2-receptors would theoretically increase the action of catecholamines on lipolysis. Yohimbine has been shown to effectively increase lipolysis.
An abundance of studies have been done investigating the lipolytic action of yohimbine in humans. In vitro studies using human adipocytes have indicated stimulatory effects of yohimbine on lipolysis when catecholamines are present.
Oral administration of yohimbine to humans has been shown to significantly elevate plasma glycerol and freefatty acids. Furthermore, the effect of yohimbine was further enhanced during physical exercise when the levels of catecholamines are further elevated. Yohimbine also appears to stimulate norepinephrine levels by increasing sympathetic nerve activity.
When yohimbine was administered during a lowenergy diet, patients lost significantly more weight than patients receiving a placebo Energy expenditure did not decline in the patients consuming yohimbine, while the placebo group experienced a 15% reduction in energy expenditure.
Safety and Toxicity
Alpharreceptors are present in a number of tissues including heart, arteries, lung, and adipose tissue. Therefore, yohimbine could react with any of these receptors and influence those tissues. However, both animal and human studies indicate that cardiovascular changes are either nonexistent or minimal following yohimbine administration.
Some side effects associated with yohimbine include feelings of panic, clumsiness, and confusion. There have also been reports of chills, nausea, and tremors. The prescription form of yohimbine is normally prescribed for impotence problems; therefore, individuals may experience heightened sexual arousal. Furthermore, there have been reports of mood disturbances and anxiety.
Another concern regarding yohimbe is the purity of the dietary supplement. Yohimbine is the major alkaloid of the plant and the active ingredient. The bark of the tree has been reported to contain 6% total alkaloids, 10-15% of which are yohimbine. Most dietary supplements have been standardized to 3% yohimbine. Therefore, a 100-mg dose of yohimbe will contain only 3 mg of yohimbine. In research studies, yohimbine is usually administered at a dose of about 0.2 mg/kg of body weight.
Tags:herbal or natural supplement yohimbine
Two years later, Kreider et al had six male cyclists and triathletes consume 1 g of tribasic sodium phosphate or a glucose placebo four times per day for 3 days before exercise. The exercise consisted of an incremental maximal cycling test or a simulated 40-km time trial on a computerized race simulator. The subjects continued supplementation for 1 extra day, and performed the same exercise again. Metabolic data were collected during 15-second intervals and venous blood samples were collected during each stage of the cycling test and every 8 km during the run. The results showed that the phosphates increased anaerobic threshold, myocardial ejection fraction and fractional shortening, VO2max (69.3 versus 75.4 mL/kg/min for placebo and phosphate groups, respectively).
Atherogenic effects of high-protein diets have been over stated, especially in regards to athletic populations. In the past, strength athletes and football players (especially offensive and defensive linemen) were known for consuming protein sources that were high in saturated fat such as various forms of fast food, whole milk, and fatty cuts of beef. Today, athletes have access to protein sources that contain minimal amounts of fat like chicken breast without skin, fish, lean cuts of beef, and egg whites. Protein supplements available today contain little to no fat. To consider a diet high in protein that is also high in fat is an outdated concept. With the variety of lean, whole-food sources of protein and the multitude of protein supplements available, some athletes may need to be advised to consume additional fat in an effort to get sufficient calories to meet their daily requirement.
The effects of caffeine were investigated at different levels of intensity. Eight untrained males cycled until exhaustion at 10% above or below anaerobic threshold after randomly receiving 5 mg/kg of caffeine or a placebo 60 minutes before exercise. There were no differences between trials when the subjects exercised at 10% above anaerobic threshold; however, ratings of perceived exertion were significantly lower (14.1 versus 16.6 for caffeine and placebo, respectively) and time to exhaustion was significantly higher during the caffeine trial at 10% below anaerobic threshold. This may be because the subjects were untrained.